Member Info for Thompi

I agree JT. This is the question that was submitted at the data update presentation.

Question 18.

Now the P1A data has been released, can it still be published in a peer reviewed journal and/or at a major oncology conference. This was Avacta’s original aim but that changed, could you clarify why?

Answer

Yes it can. We have provided a summary of key findings and have more data that we can add to those to secure presentation slots at major conferences in 2024.

Whatever the reason for FM’s departure, it was good to note that “Fiona will continue to work with the Company through a transitionary period”. (RNS)

I think CC’s US experience would also have been a big factor in any boardroom decision making. “Chris brings deep oncology research and development expertise combined with trans-Atlantic C-level experience from which the entire business will benefit as we evolve from a research organisation to one led by a strong clinical focus”.

Gmcc, just a quick post to say many thanks for all the excellent research you do and share on this board. It is very much appreciated.

Well done Griffiths_I for correcting TwoGood2Die. I don’t know how he/she managed to mistake a 30 minute presentation for one that lasted only 2 minutes and also incorrectly state that there were no slides.

Sarah Lowther is a well respected presenter/interviewer. To put any negative spin on a good natured exchange just shows a rather desperate level of fudding.

https://angleplc.com/wp-content/uploads/2024/01/ANGLE-Presentation-Proactive-Investors-11jan24.pdf

Courtesy of the Telegram board. It’s worth a read.

https://www.mdpi.com/1467-3045/46/1/50

Published today.

“Rapid advances in technology and the affordability of NGS continue to excel, paving the way for a new era of liquid biopsy.”

It’s AGL funded research and its authors are AGL employees, but it’s an interesting article nonetheless.

Sangi, required to wear a bow tie 😆, AGL investors “riff raff” 😆. You should be on the stage mate, they would be splitting their sides laughing.

Sangi, seriously? I can’t believe you have resorted to criticising the attire of the attendees and Sarah Lowther for trying to remove the mic from one of the audience, which was done in a very good humoured way. You’ve lost the plot mate. Cracking posts, I’m still laughing 😆

EC, I’m pretty certain you mean “molecular” and not “molecule” analysis?

Bojo, I agree and sentiment and momentum, like on Thursday 4th, can quickly carry the SP to the upside (and conversely to the downside). But I just think we need to be realistic, a hypothetical bid of 75p would represent a 316% increase in the SP, and a bid of £1 a 455% increase. If a pharma company was interested in acquiring AGL I think many shareholders would consider accepting 40p. (My cost average is over a £1 by the way, so I would love a stellar bid).

Thdonlywayisup, I would love your prediction of a 75p+ bid to be correct, but it is a huge premium to the current SP, and imo is unlikely & unrealistic.

Global Frontiers were interested….

Https://www.sharesmagazine.co.uk/events/event/shares-investor-evening-london-live-event-060224

Courtesy of Telegram another presentation scheduled 6th February. I’m not sure I can take all the excitement again of all the pre-presentation hype beforehand 😬😀

Jemgeee, I don’t mean to be rude, but it is rather a sensationalist headline, and could be construed as ramping.

I agree Greg, without substantiation it’s just BS. And Dealer55, the Berenberg SP target price was £1.20 on the 3rd January. Have they issued a revised one at £1.56?

Jemgeee, what do you mean “Berenberg are alluding to this”? Could you give some more detail please.

Sangi, Eisai has a market cap of $14.33 Billion. It is the 6th largest pharmaceutical company in Japan, the 39th largest globally.

I think you are being overly dismissive when you describe them as being “more of a respectable mid size company” and criticise AN for his choice of words (“huge” & “large”). It is, of course, all relative, but imo they are a major company. The contract size may not be large, but it is a foot in the door and may lead to lucrative follow on contracts. I consider it a significant achievement to sign a contract with them.

Sorry Level5 for the duplication. I was typing my reply and missed your post.

EC, the event is in front of an audience, you can register to attend in person. The presentation will then be available to watch afterwards on their YouTube channel. I don’t know how long it will take for Proactive to upload the video.

https://www.proactiveinvestors.co.uk/register/event_details/436

Bojo, is correct. I got suspended from LSE for putting a TG link on. I emailed them to find out why I couldn’t login and got this response “Please refrain from posting links to Telegram and the system won't suspend the account again…..”

“It seems that AVA028 has not been assigned to one compound but to a class of compounds (Affimer-cytokine), of which AV032 (sometimes written AV32) is just one”. Thanks for the explanation BV, I was a bit puzzled as to why the interims slide showed AV028 but the poster/video was for AV032.